| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S2012-Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo | 1 | Y | 1 Platinum/Etoposide + Atezo Induction + Maintenance | 189 | 51 | 19 | 8 | 3 | 1 | 0 | 06/28/2022 | 264 | 77 |
| 2 Platinum/Etoposide + Atezo Induction | 46 | 19 | 9 | 4 | 3 | 1 | ||||||||
| 3 Platinum/Etoposide Only | 45 | 19 | 8 | 4 | 2 | 0 | ||||||||
| 142 | 57 | 25 | 11 | 6 | 1 | |||||||||
| EAY191-S3-ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib | 1 | T | 1 Paclitaxel + Ipatasertib | 33 | 33 | 19 | 1 | 1 | 0 | 0 | 09/22/2023 | 207 | 66 | |
| 33 | 19 | 1 | 1 | 0 | 0 | |||||||||
| Yes | A071401-Prog Meningiomas,SMO/AKT/NF2 Inhib | 0 | E | Total Registrations | 53 | 3 | 1 | 0 | 0 | 0 | 02/22/2016 | 281 | 83 | |
| 53 | 3 | 1 | 0 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 9 | 1 | 1 | 0 | 0 | 0 | 02/22/2016 | |||||
| 9 | 1 | 1 | 0 | 0 | 0 | |||||||||
| No | AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | 1 | E | Total Registrations | 4 | 2 | 1 | 0 | 0 | 0 | 10/07/2021 | 215 | 114 | |
| 4 | 2 | 1 | 0 | 0 | 0 | |||||||||
| EAY191-ComboMATCH | 1 | E | Total Registrations | 21 | 10 | 2 | 0 | 0 | 0 | 08/03/2023 | 347 | 127 | ||
| 21 | 10 | 2 | 0 | 0 | 0 | |||||||||
| Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|
| SN2426 cSCC, IC Met/Inop, Amivantamab v Cetuximab | 1 Registration | 28-Jan-26 | 7 | 4 |
| AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | 2 Late Randomization Callback | 08-May-17 | 215 | 114 |
| EAY191 ComboMATCH | 2 Re-Screening | 06-Mar-23 | 347 | 127 |